Citigroup
MYGN icon

Citigroup’s Myriad Genetics MYGN Stock Holding History

Citigroup’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,700
Closed -$310K – 7001
2020
Q4 		$310K Sell
15,700
-11,700
-43% -$189K ﹤0.01% 4631
2020
Q3 		$357K Buy
27,400
+7,300
+36% +$92.4K ﹤0.01% 4148
2020
Q2 		$228K Sell
20,100
-1,200
-6% -$17K ﹤0.01% 4914
2020
Q1 		$305K Sell
21,300
-3,400
-14% -$71.8K ﹤0.01% 4344
2019
Q4 		$673K Sell
24,700
-12,900
-34% -$355K ﹤0.01% 4148
2019
Q3 		$1.08M Buy
37,600
+31,900
+560% +$930K ﹤0.01% 3563
2019
Q2 		$158K Sell
5,700
-3,400
-37% -$96K ﹤0.01% 5468
2019
Q1 		$302K Buy
9,100
+6,700
+279% +$204K ﹤0.01% 4697
2018
Q4 		$70K Sell
2,400
-4,100
-63% -$147K ﹤0.01% 5951
2018
Q3 		$299K Sell
6,500
-3,600
-36% -$160K ﹤0.01% 4843
2018
Q2 		$377K Buy
10,100
+6,800
+206% +$230K ﹤0.01% 4396
2018
Q1 		$98K Buy
3,300
+2,500
+313% +$84.6K ﹤0.01% 5633
2017
Q4 		$27K Sell
800
-4,300
-84% -$145K ﹤0.01% 6570
2017
Q3 		$185K Sell
5,100
-13,100
-72% -$374K ﹤0.01% 5053
2017
Q2 		$470K Buy
18,200
+7,200
+65% +$153K ﹤0.01% 4044
2017
Q1 		$211K Buy
11,000
+6,900
+168% +$122K ﹤0.01% 4620
2016
Q4 		$68K Buy
4,100
+2,000
+95% +$36.2K ﹤0.01% 6000
2016
Q3 		$43K Buy
2,100
+1,400
+200% +$35.5K ﹤0.01% 5762
2016
Q2 		$21K Buy
700
+300
+75% +$10.4K ﹤0.01% 6134
2016
Q1 		$15K Sell
400
-1,400
-78% -$52.8K ﹤0.01% 6666
2015
Q4 		$78K Buy
1,800
+500
+38% +$21.1K ﹤0.01% 5572
2015
Q3 		$49K Buy
1,300
+1,200
+1,200% +$42.6K ﹤0.01% 5445
2015
Q2 		$3K Buy
+100
New +$3.4K ﹤0.01% 6997

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's MYGN Position: Q1 2026 in Review

Citigroup reduced its Myriad Genetics (MYGN) stake by 53% in Q1 2026, selling an estimated $98.6K and leaving 17,007 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4374.

Citigroup first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.58M in Q4 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Citigroup held 17,007 shares of Myriad Genetics worth $76.5K as of Q1 2026.
  • Citigroup sold 18,923 Myriad Genetics shares in Q1 2026, an estimated $98.6K.
  • Myriad Genetics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4374 holding.
  • Citigroup first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Myriad Genetics position peaked at $6.58M in Q4 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.